Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous invariant natural killer T cells
- Development stage
- Phase 2
- Lead developer
- Beijing YouAn Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous invariant natural killer T (iNKT) cells are an adoptive cell therapy being developed by Beijing YouAn Hospital for the treatment of hepatocellular carcinoma (HCC). The therapeutic process involves isolating iNKT cells from a patient's peripheral blood mononuclear cells, expanding them ex vivo, and pulsing them with the glycolipid alpha-galactosylceramide (α-GalCer). These cells are a unique population of CD1d-restricted T cells that bridge the innate and adaptive immune systems. Upon reinfusion, they exert potent antitumor activity by rapidly producing Type 1 helper (Th1) cytokines, such as interferon-gamma, and releasing cytotoxic granules containing perforin and granzyme B to directly target malignant cells. The therapy is currently being evaluated in Phase 2 clinical trials, often in combination with multi-kinase inhibitors like regorafenib and immune checkpoint inhibitors, for patients with progressed HCC.
- Other names
- iNKT cellsautologous iNKT cellsalpha-galactosylceramide-pulsed autologous invariant natural killer T cells
02
Targets
GZMB (Granzyme B)iNKT TCR (Invariant natural killer T-cell receptor)IFNG (Interferon gamma)PRF1 (Zinc finger protein 395)
Beyond the preview
Go deeper on autologous invariant natural killer T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous invariant natural killer T cells.